New BOBP ETF Targets US Large-Caps Using CORE16's Proprietary Skewness Model
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 27 2025
0mins
Source: Benzinga
New ETF Launch: Exchange Traded Concepts has launched the CORE16 Best of Breed Premier Index ETF (BOBP), which aims to capitalize on market opportunities through a dynamic rebalancing strategy based on equity skewness, allowing for tactical investment decisions.
Investment Strategy: The fund utilizes a proprietary algorithm to select 50 large-cap U.S. securities, focusing on stocks with favorable performance asymmetries, and represents ETC's expansion into niche ETFs in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.550
Low
17.00
Averages
18.86
High
23.00
Current: 17.550
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
SpaceX Set to Launch Largest IPO in History
- Record IPO Valuation: SpaceX's IPO is priced at $135 per share, leading to an expected market capitalization of $1.77 trillion, marking the largest IPO in history; however, its valuation exceeds 90 times sales, indicating significant overvaluation risks.
- Historical Performance Warning: Historical data shows that the 10 largest U.S. IPO stocks have underperformed the S&P 500 by 96 percentage points since their listings, suggesting that investors might be better off investing in an S&P 500 index fund rather than participating in SpaceX's IPO.
- Strong Market Demand: While investment banks report immense demand for SpaceX's IPO, Morningstar analysts estimate its fair value at only $780 billion, implying a 56% downside from the IPO valuation of $1.77 trillion, necessitating caution among investors.
- Investor Strategy Recommendation: Although SpaceX's IPO may initially perform well, historical trends indicate it may underperform the S&P 500 in the long run, prompting a recommendation for investors to consider the Vanguard S&P 500 ETF for more stable returns.
See More
SpaceX to Go Public on June 12, Setting Record for Largest IPO
- IPO Pricing and Valuation: SpaceX has priced its IPO at $135 per share, leading to an initial market capitalization of $1.77 trillion, making it the largest IPO on record, although its valuation at 92 times sales indicates significant overvaluation risks.
- Market Demand and Performance Outlook: Underwriters report immense demand for SpaceX shares, yet historical data suggests the company may underperform the S&P 500 in the long run, indicating that investors might be better off investing in an S&P 500 index fund instead.
- Historical Performance Comparison: Data shows that over 1,100 companies listed since 2016 have averaged a 25% increase on their first trading day, but larger IPOs often face selling pressure as lock-up periods expire, a trend SpaceX may also experience.
- Investment Advice and Risks: While SpaceX's market value could potentially soar to $5 trillion post-IPO, Morningstar analysts estimate its fair value at $780 billion, suggesting a 56% downside from its IPO valuation, advising investors to remain cautious.
See More
Jim Cramer Highlights Undervalued Stocks Amid Tech Fatigue
- Investment Opportunity Identification: Jim Cramer highlights that as tech stocks lose momentum, investors should focus on undervalued stocks, particularly JPMorgan Chase, which is trading at a forward P/E of about 13, down from 15 at the start of the year, indicating its attractiveness.
- Healthcare Sector Potential: Cramer believes Johnson & Johnson may present a more appealing investment option due to its drug pipeline and growing medical technology business, although he remains positive on Eli Lilly as well.
- Consumer Goods Stability: Cramer favors Kimberly-Clark for its strong brand portfolio and attractive dividend yield, with the planned merger with Kenvue expected to further enhance its market position.
- Restaurant Sector Rebound: Cramer points to McDonald's and Yum! Brands, arguing that the tech sector's popularity has undervalued these stocks, particularly with Yum! Brands considering the sale of Pizza Hut, which sweetens its investment case.
See More
Investors Should Consider Out-of-Favor Sectors
- Investment Opportunity Identification: CNBC's Jim Cramer suggests that investors should consider out-of-favor sectors, particularly as tech stocks may retreat, highlighting potential beneficiaries like JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum! Brands, and Kraft Heinz.
- Financial Sector Potential: Cramer points out that JPMorgan's forward P/E ratio is around 13 times, down from 15 at the beginning of the year, and despite a 7% decline year-to-date, its value as a quality franchise remains attractive, indicating investment opportunities amid economic slowdown concerns.
- Healthcare Sector Outlook: Cramer believes Johnson & Johnson's drug pipeline and growing medical technology business present significant growth potential, suggesting it may offer a more attractive investment opportunity than Eli Lilly, while advising investors to buy slowly due to market uncertainties.
- Consumer Goods and Restaurant Sector: Cramer highlights Kimberly-Clark's household brand portfolio and appealing dividend yield, along with the investment value of McDonald's and Yum! Brands, particularly with Yum! potentially selling Pizza Hut, which enhances its investment appeal.
See More
Trump Bull Market May End, Pharma Stocks to Continue Winning
- Market Performance Review: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor demand for high-growth companies, particularly in innovative sectors like AI and quantum computing.
- Eli Lilly's Growth Potential: Eli Lilly (LLY) leads the obesity drug market with products like Mounjaro and Zepbound, which continue to see revenue growth in double and triple digits, and the newly launched oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson (JNJ) reported sales growth in its innovative medicines and medtech sectors, with an 11% increase in innovative medicine sales and a 7.7% rise in medtech, totaling nearly $24 billion in sales, demonstrating resilience amid economic fluctuations.
- Future Growth Targets: Johnson & Johnson aims to achieve $100 billion in annual revenue this year and double-digit growth by the end of the decade, supported by its portfolio of 28 products generating over $1 billion annually, which is expected to drive stock price increases.
See More
S&P 500 Rises 23% Since Trump's Inauguration Amid Growth Stocks Surge
- Market Growth Trend: Since President Trump's inauguration, the S&P 500 has surged over 23%, reflecting strong investor interest in high-growth sectors, particularly in innovative areas like artificial intelligence and quantum computing, which have driven overall market gains.
- Pharmaceutical Market Leader: Eli Lilly is leading the obesity drug market, with its products Mounjaro and Zepbound experiencing revenue growth in double and triple digits, and the recent launch of the oral weight loss drug Foundayo is expected to broaden its market reach.
- Strong Financial Performance: Johnson & Johnson reported nearly 10% sales growth in its innovative medicines and medtech sectors, with total sales exceeding $24 billion in the latest quarter, indicating robust growth potential in the healthcare market.
- Future Growth Expectations: Johnson & Johnson aims to achieve $100 billion in annual revenue by 2023 and anticipates double-digit growth by the end of the decade, suggesting that demand for its medical products will remain strong even amid economic fluctuations, positioning the stock for continued appreciation.
See More
SpaceX Set to Launch Largest IPO in History
- Record IPO Valuation: SpaceX's IPO is priced at $135 per share, leading to an expected market capitalization of $1.77 trillion, marking the largest IPO in history; however, its valuation exceeds 90 times sales, indicating significant overvaluation risks.
- Historical Performance Warning: Historical data shows that the 10 largest U.S. IPO stocks have underperformed the S&P 500 by 96 percentage points since their listings, suggesting that investors might be better off investing in an S&P 500 index fund rather than participating in SpaceX's IPO.
- Strong Market Demand: While investment banks report immense demand for SpaceX's IPO, Morningstar analysts estimate its fair value at only $780 billion, implying a 56% downside from the IPO valuation of $1.77 trillion, necessitating caution among investors.
- Investor Strategy Recommendation: Although SpaceX's IPO may initially perform well, historical trends indicate it may underperform the S&P 500 in the long run, prompting a recommendation for investors to consider the Vanguard S&P 500 ETF for more stable returns.
See More
SpaceX to Go Public on June 12, Setting Record for Largest IPO
- IPO Pricing and Valuation: SpaceX has priced its IPO at $135 per share, leading to an initial market capitalization of $1.77 trillion, making it the largest IPO on record, although its valuation at 92 times sales indicates significant overvaluation risks.
- Market Demand and Performance Outlook: Underwriters report immense demand for SpaceX shares, yet historical data suggests the company may underperform the S&P 500 in the long run, indicating that investors might be better off investing in an S&P 500 index fund instead.
- Historical Performance Comparison: Data shows that over 1,100 companies listed since 2016 have averaged a 25% increase on their first trading day, but larger IPOs often face selling pressure as lock-up periods expire, a trend SpaceX may also experience.
- Investment Advice and Risks: While SpaceX's market value could potentially soar to $5 trillion post-IPO, Morningstar analysts estimate its fair value at $780 billion, suggesting a 56% downside from its IPO valuation, advising investors to remain cautious.
See More
Jim Cramer Highlights Undervalued Stocks Amid Tech Fatigue
- Investment Opportunity Identification: Jim Cramer highlights that as tech stocks lose momentum, investors should focus on undervalued stocks, particularly JPMorgan Chase, which is trading at a forward P/E of about 13, down from 15 at the start of the year, indicating its attractiveness.
- Healthcare Sector Potential: Cramer believes Johnson & Johnson may present a more appealing investment option due to its drug pipeline and growing medical technology business, although he remains positive on Eli Lilly as well.
- Consumer Goods Stability: Cramer favors Kimberly-Clark for its strong brand portfolio and attractive dividend yield, with the planned merger with Kenvue expected to further enhance its market position.
- Restaurant Sector Rebound: Cramer points to McDonald's and Yum! Brands, arguing that the tech sector's popularity has undervalued these stocks, particularly with Yum! Brands considering the sale of Pizza Hut, which sweetens its investment case.
See More
Investors Should Consider Out-of-Favor Sectors
- Investment Opportunity Identification: CNBC's Jim Cramer suggests that investors should consider out-of-favor sectors, particularly as tech stocks may retreat, highlighting potential beneficiaries like JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum! Brands, and Kraft Heinz.
- Financial Sector Potential: Cramer points out that JPMorgan's forward P/E ratio is around 13 times, down from 15 at the beginning of the year, and despite a 7% decline year-to-date, its value as a quality franchise remains attractive, indicating investment opportunities amid economic slowdown concerns.
- Healthcare Sector Outlook: Cramer believes Johnson & Johnson's drug pipeline and growing medical technology business present significant growth potential, suggesting it may offer a more attractive investment opportunity than Eli Lilly, while advising investors to buy slowly due to market uncertainties.
- Consumer Goods and Restaurant Sector: Cramer highlights Kimberly-Clark's household brand portfolio and appealing dividend yield, along with the investment value of McDonald's and Yum! Brands, particularly with Yum! potentially selling Pizza Hut, which enhances its investment appeal.
See More
